The global molecular diagnostics market size is estimated to grow from $15.9 billion in 2024 to $30.9 billion by 2035, at a CAGR of 6.2% during the forecast period, till 2035. The anticipated market growth is accredited to the significant surge in demand across the regional and global markets for the products and services offered by the Molecular Diagnostics Market. The latest study provides readers with a granular analysis of the major developmental elements of the global market, potential business avenues, and the overall market dynamics. The report has been specially curated to offer a deep understanding of the competitive terrain of the global market, highlighting the leading market rivals, their market positions, product portfolios, gross revenue shares, profit margins, pricing analysis, sales network & distribution channels, and financial standing.

Test Type

Laboratory Testing

Point-of-Care Testing

Type of Sample

Blood, Serum and Plasma

Urine

Others

Type of Technology

Polymerase Chain Reaction (PCR)

In situ Hybridization

Isothermal Nucleic Acid Amplification Technology

Next Generation Sequencing

Microarrays

Mass Spectrometry

Others

Key Geographical Regions

North America

Europe

Asia

MENA

Latin America

Rest of the World

The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the Molecular Diagnostics Market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.

The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the Molecular Diagnostics Market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Molecular Diagnostics Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/molecular-diagnostics-market.html

About Roots Analysis

Roots Analysisis a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

Sales@rootsanalysis.com

However, owing to several manufacturing related complexities, many contemporary drug developers have demonstrated a preference to rely on CMOs for the supply of GMP grade lipids.

The lipid contract manufacturing market size reaches USD 5.6 billion by 2030, growing at a CAGR of 10%.

Key Market Insights

Around 60 companies claim to offer contract manufacturing services for lipids

The majority (39%) of the industry stakeholders are mid-sized companies, followed by small players (32%) and large / very large firms (29%). In addition, 35% of the CMOs engaged in this domain offer services for liposomes / lipid nanoparticles, followed by those providing services for phospholipids (17%).

Several partnerships were established in this domain, during the period 2016-2021

Acquisitions and manufacturing agreements (23% each) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Majority (49%) of the deals were inked for lipid-based FDFs, followed by those signed for lipid-based excipients (30%).

Expansion activity in this domain has grown at a CAGR of ~55%, between 2016 and 2021

Most of such initiatives were focused on the establishment of new facilities (35%) and expanding existing facilities (35%), followed by those carried out for capacity expansion (30%). Further, majority of the investments were made in facilities located in North America (67%) and Europe (28%).

Currently available lipid contract manufacturing capacity is estimated to be over 0.1 million liters

Around 40% of the total capacity is installed for carrying out commercial scale operations. Further, in terms of geography, the maximum lipid contract manufacturing capacity (close to 65%) is installed in North America.

North America and Europe are anticipated to capture close to 70% of the market share, by 2030

In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (11.4%), over the next nine years. Further, in 2030, the majority share (~55%) of contract manufacturing revenues is likely to be generated from projects focused on liposomes / lipid nanoparticles and phospholipids.

Key Questions Answered

Who are the leading players engaged in offering lipid contract manufacturing services?

Which global regions are considered as key hubs for contract manufacturing of lipid products?

Which partnership models are most commonly adopted by stakeholders in this industry?

What different expansion initiatives have been undertaken by lipid contract manufacturers?

Which factors are likely to influence the decision of whether to carry out lipid manufacturing in-house or outsource these operations?

What is current, global lipid manufacturing capacity (in litres) of contract manufacturers?

How is the current and future market opportunity likely to be distributed across key market segments?

The USD 5.5+ billion (by 2030) financial opportunity associated with lipid contract manufacturing market has been analyzed across the following segments:

Type of Lipid

Liposomes / Lipid Nanoparticles

Phospholipids

PEGylated lipids

Ionizable lipids (Cationic / Anionic)

Triglycerides

Sphingolipids

Neutral lipids

Others

Company Size

Small

Mid-sized

Large / Very Large

Scale of Operation

Preclinical

Clinical

Commercial

Key Geographical Regions

North America

Europe

Asia Pacific

MENA

Latin America

Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, a significant proportion of manufacturing operation are presently outsourced. This can be attributed to the fact that most products in this field are specialized formulations and therefore, require advanced expertise. The report includes detailed transcripts of discussions held with the following experts:

Asha Van Rooijen (Founder and Chief Executive Officer, Liposoma)

Rahul Keswani (Associate Director, Formulation Development, Exelead)

John Riley (Director, Process Development-Chemistry, BioVectra) and Clement Mugabe (Acting Manager, Biotech Process Development, BioVectra)

The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), details related to its service portfolio, manufacturing facilities, recent developments and an informed future outlook.

Ardena

Avanti Polar Lipids

CordenPharma

Creative Biolabs

Evonik

Exelead

FormuMax Scientific

Fresenius Kabi

Fujifilm

Merck KGaA

Nagase Medicals

Nippon Fine Chemical

T&T Scientific

TTY Biopharm

VCARE Bio Labs

Contact:

Gaurav Chaudhary

Gaurav.Chaudhary@rootsanalysis.com